Table 3 Best treatment response by the RECIST criteria
From: Phase II trial of sagopilone, a novel epothilone analog in metastatic melanoma
Best treatment response | N | % |
|---|---|---|
Complete response | 1 | 2.9 |
Partial response | ||
Confirmed | 2 | 5.7 |
Unconfirmed | 1 | 2.9 |
Stable disease | 8 | 22.9 |
Progressive disease | 23 | 65.7 |
Total | 35 | 100 |
